Nadim Ahmed Sells 16,381 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) CEO Nadim Ahmed sold 16,381 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $13.62, for a total transaction of $223,109.22. Following the transaction, the chief executive officer directly owned 404,318 shares in the company, valued at $5,506,811.16. The trade was a 3.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Nadim Ahmed also recently made the following trade(s):

• On Tuesday, December 23rd, Nadim Ahmed sold 9,922 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $10.01, for a total transaction of $99,319.22.

Cullinan Therapeutics Stock Up 2.0%

Shares of NASDAQ:CGEM opened at $14.27 on Wednesday. The firm has a fifty day moving average of $11.41 and a two-hundred day moving average of $9.27. The firm has a market capitalization of $843.01 million, a P/E ratio of -4.31 and a beta of -0.09. Cullinan Therapeutics, Inc. has a 12-month low of $5.68 and a 12-month high of $14.56.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on CGEM shares. BTIG Research upped their target price on Cullinan Therapeutics from $32.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, November 24th. Guggenheim initiated coverage on Cullinan Therapeutics in a research note on Monday, February 2nd. They issued a “buy” rating and a $30.00 price target for the company. Wall Street Zen lowered shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, February 8th. New Street Research set a $26.00 target price on shares of Cullinan Therapeutics in a research note on Thursday, November 20th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $30.00 target price on shares of Cullinan Therapeutics in a research report on Thursday, January 8th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Cullinan Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $29.33.

Key Headlines Impacting Cullinan Therapeutics

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: Bullish independent thesis — A Seeking Alpha write‑up upgrades Cullinan to a Buy, highlighting a deep T‑cell engager pipeline (notably CLN‑049 showing ~30% CR in AML), a strong cash runway (~$430M+), and a clear regulatory path that supports upside expectations. Seeking Alpha: Thesis Strengthening For This T-Cell Engager Specialist
• Positive Sentiment: Investor conference participation — Management (CEO Nadim Ahmed and CMO Jeffrey Jones) announced attendance at upcoming investor conferences, which increases investor access to clinical updates and can support multiple‑stakeholder visibility. GlobeNewswire: Cullinan Therapeutics to Participate in Upcoming Investor Conferences
• Positive Sentiment: Analyst momentum — Multiple firms have issued Buy/Outperform ratings and lifted price targets in recent months (consensus/average target materially above current levels), which can attract momentum buyers. MarketBeat: CGEM analyst coverage
• Neutral Sentiment: Technical/fundamental backdrop — The stock is trading above the 50‑ and 200‑day moving averages and is well above its 52‑week low, reflecting short‑term strength; market cap and high institutional ownership (~86%) mean moves can be amplified by flows. MarketBeat: CGEM profile
• Negative Sentiment: Clustered insider sales — Several insiders (CEO Nadim Ahmed, CFO Mary Kay Fenton and others) sold shares around Feb 20 (combined ~20k+ shares across multiple filings). While the percentages trimmed are modest (low single digits), simultaneous sales by senior executives can create near‑term selling pressure and raise questions for some traders. InsiderTrades: CGEM insider transactions

Institutional Investors Weigh In On Cullinan Therapeutics

A number of large investors have recently added to or reduced their stakes in CGEM. Lynx1 Capital Management LP raised its position in shares of Cullinan Therapeutics by 31.0% in the third quarter. Lynx1 Capital Management LP now owns 5,766,090 shares of the company’s stock valued at $34,193,000 after purchasing an additional 1,365,248 shares during the period. Blue Owl Capital Holdings LP boosted its holdings in shares of Cullinan Therapeutics by 5.2% during the 3rd quarter. Blue Owl Capital Holdings LP now owns 2,510,972 shares of the company’s stock worth $14,890,000 after buying an additional 125,000 shares during the period. Franklin Resources Inc. grew its stake in Cullinan Therapeutics by 0.4% in the 2nd quarter. Franklin Resources Inc. now owns 2,228,160 shares of the company’s stock valued at $16,778,000 after buying an additional 8,399 shares during the last quarter. State Street Corp grew its stake in Cullinan Therapeutics by 31.0% in the 4th quarter. State Street Corp now owns 2,197,338 shares of the company’s stock valued at $22,742,000 after buying an additional 520,024 shares during the last quarter. Finally, Affinity Asset Advisors LLC raised its holdings in Cullinan Therapeutics by 632.4% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,932,106 shares of the company’s stock worth $19,997,000 after acquiring an additional 1,668,289 shares during the period. Institutional investors own 86.31% of the company’s stock.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.